Cargando…
Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ
Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the biological factors pre-disposing an individual to develop ADA are poorly characterized. Thus, there is an unmet clinical need fo...
Autores principales: | Waddington, Kirsty E., Papadaki, Artemis, Coelewij, Leda, Adriani, Marsilio, Nytrova, Petra, Kubala Havrdova, Eva, Fogdell-Hahn, Anna, Farrell, Rachel, Dönnes, Pierre, Pineda-Torra, Inés, Jury, Elizabeth C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380268/ https://www.ncbi.nlm.nih.gov/pubmed/32765529 http://dx.doi.org/10.3389/fimmu.2020.01527 |
Ejemplares similares
-
Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors?
por: Pineda-Torra, Inés, et al.
Publicado: (2021) -
Impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults
por: Parikh, Chinar R., et al.
Publicado: (2021) -
Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach
por: Robinson, George A, et al.
Publicado: (2020) -
Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE
por: Robinson, George A., et al.
Publicado: (2021) -
Transcriptional Regulation of T-Cell Lipid Metabolism: Implications for Plasma Membrane Lipid Rafts and T-Cell Function
por: Robinson, George A., et al.
Publicado: (2017)